Arbutus Biopharma ABUS
$4.02 −$0.05 (-1.23%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $3.98 -1.00%
Open$4.01
Prev close$4.07
Day range$3.97 – $4.09
Volume2.99M
Market cap$616.24M
P/E (TTM)3.6
Dividend yield–
ABUS Stock News
Headlines matching Arbutus Biopharma or the ABUS ticker, most recent first.
- Arbutus Biopharma: Arbutus Biopharma Corporation - Broker-To-Broker Settlement/Exercise Considerations Option Symbol: ABUS
- Arbutus Biopharma: Arbutus Biopharma Corporation - Partial Self Tender Offer Option Symbol: ABUS
- Earnings Flash (ABUS) Arbutus Biopharma Posts Q1 EPS $0.87, Vs. FactSet Est of $0.03 Loss Negative
- Earnings Flash (ABUS) Arbutus Biopharma Posts 2025 Total Revenue $14.1M, Vs. FactSet Est of $13.6M
- Earnings Flash (ABUS) Arbutus Biopharma Posts 2025 Loss $0.17 a Share, Vs. FactSet Est of $0.19 Loss Negative
- ABUS Stock Has Given up Its Prior Gain. Arbutus Biopharma Shares Were Trading Higher After the Company Presented Clinical Trial Data From Its Two HBV Assets. Positive
- JMP Securities Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5
- Earnings Flash (ABUS) Arbutus Biopharma Corporation Reports Q3 Revenue $529,000, Vs. FactSet Est of $1.3M
- H.C. Wainwright Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5
- Jefferies Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $7 Positive
- Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $4
- JMP Securities Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $5 Positive
- Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $4.5 Positive
- Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $5 Positive
- H.C. Wainwright Keeps Their Buy Rating on Arbutus Biopharma (ABUS)
No comments yet — be the first to weigh in on ABUS.
Sign in to join the discussion.